CDAB XI, LP – Trademark Portfolio

Entity Type: 13

CDAB XI, LP holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 30 (Staple Foods) — 10 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 3 Nice Classification classes. Currently, 9 trademarks are registered. Notable registered marks include CAPPIO, ALDECOA, BRIGADE, EXIMIUS, and UPTEAMUS. The owner is based in HOUSTON, TX.

5610 CLINTON DR., BUILDING B

HOUSTON, TX 77020

12 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CDAB XI, LP's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

30
Staple Foods (10 filings)

Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations

40
Treatment & Processing (1 filing)

Treatment of materials

33
Wine & Spirits (1 filing)

Alcoholic beverages (except beers)

Frequently Asked Questions

How many trademarks does CDAB XI, LP have?

CDAB XI, LP has 12 U.S. trademarks filed with the USPTO. Of these, 9 registered, 2 abandoned, 1 cancelled.

What trademark classes does CDAB XI, LP file in?

CDAB XI, LP files trademarks across 3 Nice Classification classes. The most active classes are Class 30 (Staple Foods), Class 40 (Treatment & Processing), Class 33 (Wine & Spirits). Class 30 covers coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations.

What are CDAB XI, LP's most well-known trademarks?

CDAB XI, LP's registered trademark portfolio includes well-known marks such as CAPPIO, ALDECOA, BRIGADE, EXIMIUS, and UPTEAMUS. These are among 9 currently registered trademarks in the portfolio.

What is CDAB XI, LP's trademark registration success rate?

CDAB XI, LP has a 75% trademark registration rate, with 9 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.